BRAF and neoplasm: In addition, BRAF p.V600E, p.G466V, and p.L597R, as well as BRCA2 mutations, were also considered actionable based on the observations from other tumor types (Gautschi et al., 2015; Robert et al., 2015; Pujade-Lauraine et al., 2017).